• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

    2/10/22 5:01:03 PM ET
    $ALC
    Ophthalmic Goods
    Health Care
    Get the next $ALC alert in real time by email
    SC 13G/A 1 formsc13ga.htm FORM SC 13G/A WCM Investment Management: Form SC 13G/A - Filed by newsfilecorp.com

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

    Alcon Inc

    (Name of Issuer)

     

    Common

    (Title of Class of Securities)

     

    H01301128

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     [X]  Rule 13d-1(b)

     [_]  Rule 13d-1(c)

     [_]  Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    SCHEDULE 13G

    CUSIP No.           H01301128


    1 Names of Reporting Persons

    WCM Investment Management, LLC
    2 Check the appropriate box if a member of a Group (see instructions)

    (a)  [ ]
    (b)  [ ]
    3 Sec Use Only

         
    4 Citizenship or Place of Organization

    Delaware
    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:
     
    5 Sole Voting Power

    26,016,575
    6 Shared Voting Power

    0
    7 Sole Dispositive Power

    26,016,575
    8 Shared Dispositive Power

    0
    9 Aggregate Amount Beneficially Owned by Each Reporting Person

    26,016,575
    10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    [ ]
    11 Percent of class represented by amount in row (9)

    5.21%
    12 Type of Reporting Person (See Instructions)

    IA

    Page 2 of 5


    Item 1.

    (a) Name of Issuer: Alcon Inc

    (b) Address of Issuer's Principal Executive Offices: rue Louis-d'Affry 6, Avenue Louis-Casai 58 Cointrin, Fribourg, FR 1701, Switzerland

    Item 2.

    (a) Name of Person Filing: WCM Investment Management, LLC

    (b) Address of Principal Business Office or, if None, Residence:  281 Brooks Street, Laguna Beach, California 92651

    (c) Citizenship: Delaware

    (d) Title and Class of Securities: Common

    (e) CUSIP No.: H01301128

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a) [_] Broker or dealer registered under Section 15 of the Act;

    (b) [_] Bank as defined in Section 3(a)(6) of the Act;

    (c) [_] Insurance company as defined in Section 3(a)(19) of the Act;

    (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940;

    (e) [X] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

    (f) [_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

    (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

    (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

    (j) [_] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

    (k) [_] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

    Page 3 of 5


    Item 4. Ownership

    (a) Amount Beneficially Owned:     26,016,575

    (b) Percent of Class:  5.21%

    (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote: 26,016,575

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 26,016,575

    (iv) Shared power to dispose or to direct the disposition of: 0

    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [    ].

    Item 6. Ownership of more than Five Percent on Behalf of Another Person.

    Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

    Item 8. Identification and classification of members of the group.

    Item 9. Notice of Dissolution of Group.

    Item 10. Certifications.

    Page 4 of 5


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:  February 10, 2022

    /s/ Signature

    Name/Title David A. Brewer, SVP/Chief Compliance Officer

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative.  If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference.  The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Attention:  Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

     

    Page 5 of 5


    Get the next $ALC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALC

    DatePrice TargetRatingAnalyst
    5/20/2025Buy → Hold
    Deutsche Bank
    5/14/2025$102.00 → $99.00Buy
    BTIG Research
    3/28/2025$107.00 → $110.00Buy
    Needham
    3/25/2025Neutral → Buy
    BofA Securities
    1/24/2025$108.00 → $106.00Buy
    Needham
    1/10/2025Neutral → Buy
    Redburn Atlantic
    12/17/2024$103.00 → $108.00Buy
    Needham
    11/12/2024Buy
    Needham
    More analyst ratings

    $ALC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alcon downgraded by Deutsche Bank

      Deutsche Bank downgraded Alcon from Buy to Hold

      5/20/25 8:02:28 AM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • BTIG Research reiterated coverage on Alcon with a new price target

      BTIG Research reiterated coverage of Alcon with a rating of Buy and set a new price target of $99.00 from $102.00 previously

      5/14/25 11:06:26 AM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Needham reiterated coverage on Alcon with a new price target

      Needham reiterated coverage of Alcon with a rating of Buy and set a new price target of $110.00 from $107.00 previously

      3/28/25 7:39:07 AM ET
      $ALC
      Ophthalmic Goods
      Health Care

    $ALC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

      In pivotal Phase 3 trials, TRYPTYR demonstrated rapid natural tear production as early as Day 11-2 TRYPTYR is a first-in-class TRPM8 receptor agonist that rapidly stimulates natural tear production in patients with Dry Eye Disease (DED)3 Approximately 38 million individuals in the U.S. are living with DED, yet less than 10% of diagnosed patients are being treated with a prescription product4 Ad hoc announcement pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. Food and Drug Administration (FDA) has approved TRYPTYR® (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, f

      5/28/25 4:40:00 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS

      First-quarter 2025 sales of $2.5 billion, in line on a reported basis, or up 3% constant currency1 (cc), versus first-quarter 2024 First-quarter 2025 diluted EPS of $0.70; core diluted EPS2 of $0.73 Generated $384 million cash from operations and $278 million free cash flow3 Dividend of CHF 0.28 per share approved by shareholders at the Annual General Meeting on May 6, 2025 Launched rich pipeline of innovative products, including Voyager, Precision7 and Systane Pro PF in Q1 2025; Unity VCS and PanOptix Pro in May 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31

      5/13/25 4:30:00 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Alcon Announces Results of 2025 Annual General Meeting

      Shareholders approve all agenda items presented Deborah Di Sanzo elected as new member of the Board 2024 Compensation Report and Report on Non-Financial Matters approved in advisory votes Alcon Inc. (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2025 Annual General Meeting ("AGM"). A total of 332,704,408 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,308,176.32, were represented at today's AGM. Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who stood f

      5/6/25 4:30:00 PM ET
      $ALC
      Ophthalmic Goods
      Health Care